Carla Solé

TL;DR: The current state of knowledge regarding circRNAs, their synthesis, function, and association with cancer are considered, and some of the challenges that remain to be resolved are reviewed if this emerging class of RNAs are really to become useful in the clinic.

TL;DR: One of the most promising classes of circulating cancer biomarkers: microRNAs (miRNAs) is reviewed, which means that cancer detection may be earlier and that the ability to monitor disease progression and/or treatment response represents a paradigm shift in the treatment of cancer patients.

TL;DR: This review focuses on the emerging potential for different classes of RNA as cancer biomarkers, and in particular the barriers and limitations that remain to be overcome if these molecules are to become part of routine clinical practice.

TL;DR: The new monoclonal anti-SOX11 antibodies are characterized, suitable for Western blot assay and immunohistochemistry (IHC) on formalin-fixed paraffin-embedded tissue and compared with those of other routinely used antibodies.

TL;DR: PBL-T expands the clinicopathologic spectrum of the transformation of low-grade B-cell lymphomas by occurring in 3 chronic lymphocytic leukemias and 3 follicular lymphomas, which are clinically, histologically, and phenotypically similar to primary plasmablastic lymphomas.